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Mycobacterial growth inhibitionBackground: Vaccination with Bacillus Calmette Guerin (BCG) protects infants against childhood tubercu-
losis however the immune mechanisms involved are not well understood. Further elucidation of the
infant immune response to BCG will aid with the identification of immune correlates of protection
against tuberculosis and with the design of new improved vaccines. The purpose of this study was to
investigate BCG-induced CD4+ T-cell responses in blood samples from infants for cytokine secretion pro-
files thought to be important for protection against tuberculosis and compare these to PBMC-mediated
in vitro mycobacterial growth inhibition.
Methods: Blood from BCG-vaccinated or unvaccinated infants was stimulated overnight with
Mycobacterium tuberculosis (M. tb) purified protein derivative (PPD) or controls and intracellular cytokine
staining and flow cytometry used to measure CD4+ T-cell responses. PBMC cryopreserved at the time of
sample collection were thawed and incubated with live BCG for four days following which inhibition of
BCG growth was determined.
Results: PPD-specific IFNc+TNFa+IL-2+CD4+ T-cells represented the dominant T-cell response at
4 months and 1 year after infant BCG. These responses were undetectable in age-matched unvaccinated
infants. IL-17+ CD4+ T-cells were significantly more frequent in vaccinated infants at 4 months but not
at 1-year post-BCG. PBMC-mediated inhibition of mycobacterial growth was significantly enhanced at
4 months post-BCG as compared to unvaccinated controls. In an analysis of all samples with both data-
sets available, mycobacterial growth inhibition correlated significantly with the frequency of polyfunc-
tional (IFNc+TNFa+IL-2+) CD4+ T-cells.
Conclusions: These data suggest that BCG vaccination of infants induces specific polyfunctional T-helper-
1 and T-helper-17 responses and the ability, in the PBMC compartment, to inhibit the growth of
mycobacteria in vitro.We also demonstrate that polyfunctional T-helper-1 cells may play a role in growth
inhibition as evidenced by a significant correlation between the two.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
A major challenge in the field of tuberculosis (TB) vaccinology is
the need for a better understanding of how Bacillus Calmette-
Guerin (BCG), the only licensed vaccine in use against TB, confers
protection in some populations and settings but not others [1–3].Knowledge of the mechanisms underlying this difference is vital
for the ongoing search for a better vaccine. One TB vaccine candi-
date that had proved efficacious in pre-clinical animal models
[4,5] did not give infants significant protection from TB disease
[6]. In that clinical trial, the vaccine, MVA85A, was administered
to infants already vaccinated at birth with BCG with the aim of
enhancing any BCG-mediated protection. That this did not occur
has prompted the suggestion that the protection afforded by BCG
alone may be difficult to improve upon and as such, its mecha-
nisms of action deserve greater attention if this is to happen [7].
Our group has previously provided an immunological descrip-
tion of the different responses to BCG in United Kingdom (UK)
and African populations in which the efficacy of BCG differs.
Malawian adolescents displayed high baseline immune responses
S.G. Smith et al. / Vaccine 34 (2016) 5298–5305 5299to mycobacterial antigen and BCG did not enhance these. In the UK,
adolescents displayed low baseline responses which were
increased significantly following BCG [8]. These observations were
consistent with the hypothesis that exposure to non-tuberculous
mycobacteria (NTM) was masking the response to BCG [9]. In sub-
sequent reports we expanded this description to infants where,
although pre-exposure to NTM was unlikely given the very young
age of the study group, differences in immune response were still
observed between the two settings. UK infants made stronger T
helper (Th)-1-type responses including IFNc whereas Malawian
infants made stronger Th-2 and regulatory-type responses [10].
Although Th-1 responses, including cytokines such as IFNc and
antigen-specific CD4+ T-cells, have been reported not to correlate
with protection against, or risk of, TB disease [11–15], they remain
a focus of interest for TB vaccinologists due to contrasting evidence
where these cells do seem to correlate with protection against TB
[16] as well as the strong evidence in favour of their importance
based on studies of patients with IFNc signaling deficiencies
[17,18] or with HIV infection and low CD4 counts [19] who are
both susceptible to TB.
A recent development in the field of TB biomarker discovery has
been the establishment of techniques that allow the measurement
of mycobacterial growth inhibition in vitro. This assessment of the
capacity of a compartment such as whole blood or peripheral blood
mononuclear cells (PBMC) to inhibit the growth of mycobacteria
represents an unbiased surrogate marker of protection against TB
and allows for investigations into the potential roles of immune
mechanisms of interest in mediating this ‘‘protective” effect [20–
23].
In light of the recent evidence [24] that BCG vaccination in high
latitude, low NTM settings such as the UK might provide important
information regarding BCG-induced protective immunity, we
hypothesized that the cytokine immune responses we previously
described in UK infants would originate from antigen-specific
helper T-cells. We report here our findings that BCG vaccination
does indeed induce long lasting, polyfunctional Th-1 cellular
responses as well as a more transient Th-17 response in UK infants.
We also show that BCG vaccination induces PBMC-mediated
mycobacterial growth inhibition and that polyfunctional Th-1
responses may play a role in this.2. Materials and methods
2.1. Study participants and sample collection
Healthy infants, born in the UK to mothers with no history of
chronic illness including HIV infection, were recruited after written
informed consent was obtained from parents. Depending upon
local health service policy, infants either received a single dose of
intradermal BCG (BCG Vaccine Danish Strain 1331, Staten
Serum Institute, Copenhagen, Denmark) at community clinics
(median vaccination age: 5.6 weeks, interquartile range (IQR):
4.3–8.0 weeks) or did not receive BCG. Heparinised venous blood
samples were obtained from infants at two time points selected
to provide data at distinct intervals (4 months and 1 year) follow-
ing vaccination or at age-matched time points in unvaccinated
infants. Due to variations in availabilities of infant participants
and parents, actual median sampling time points were 15.3 weeks
(IQR: 14.4–18.0) and 56.3 weeks (IQR: 54.9–58.0). Ethical approval
for the study was granted by the National Research Ethics Service
Committee London-East (11/LO/0363) and by the Ethics Commit-
tee of the London School of Hygiene and Tropical Medicine.2.2. Diluted whole blood intracellular cytokine staining (ICS) assay
Venous blood (0.5 mL) was diluted 1:1 with warm Iscove’s
Modified Dulbecco’s Medium (Lonza, Belgium) in 15 mL centrifuge
tubes (Corning Inc. NY). Diluted blood was incubated alone (med-
ium only negative control), with 10 lg/mlM. tb PPD batch RT50 for
in vitro use; Statens Serum Institute, Copenhagen, Denmark) or
with 5 lg/ml staphylococcus enterotoxin B (SEB; Sigma, UK) as a
positive control. Co-stimulatory antibodies (2 lg/ml each of anti-
CD28 and anti-CD49d (BD Biosciences, Oxford, UK) [25]) were
added to all antigen and control tubes. Assay tubes were incubated
with loose lids for 2 h at 37 C after which 3 lg/ml of brefeldin A
(Sigma, UK) was added to all tubes which were then incubated
for a further 18 h at 37 C. The average time between venipuncture
and the initiation of ICS assay stimulations was 3 h 16 min (SD:
56 min). Following incubations diluted blood was incubated with
10 volumes of 1x PharmLyse solution (BD Biosciences, Oxford,
UK) at room temperature for 10 min to lyse red blood cells, cen-
trifuged and washed with 3 mL PBS. Prior to permeabilisation, pel-
leted cells were surface stained with Vivid live/dead reagent
(Molecular Probes), anti-CD4-APC-H7 (BD Biosciences), anti-
CD19-efluor450 and anti-CD14-efluor450 (eBiosciences) for
30 min at 4 C. After washing in PBS + 0.1% BSA + 0.01% sodium
azide, cells were permeabilised with Cytofix/Cytoperm reagent
(BD Biosciences) at 4 C for 20 min, washed in Perm Wash
buffer (BD Biosciences) and stained with anti-CD3-Horizon-V500,
anti-IL-2-FITC, anti-TNFa-PE-Cy7 (BD Biosciences), anti-IL-17-
efluor660, anti-IL-10-PE (eBiosciences) and anti-IFNc-PerCP-
Cy5.5 (Biolegend) for 30 min at room temperature. Cells were
finally resuspended in 250 lL 1% paraformaldehyde (Sigma, UK)
and filtered prior to acquisition. Data was acquired using an LSRII
flow cytometer (BD Biosciences) configured with 3 lasers and 10
detectors and FACSDiva acquisition software (BD Biosciences).
Compensation was performed using tubes of CompBeads (BD Bio-
sciences) individually stained with each fluorophor and compensa-
tion matrices were calculated with FACSDiva.
2.3. PBMC cryopreservation and in vitro mycobacterial growth
inhibition assay
For infant blood samples where enough material was available
following whole blood ICS assays, PBMC were prepared by density
centrifugation and cryopreserved. Briefly, blood diluted 1/3 in
HBSS (Invitrogen) was layered over Histopaque 1077 (Sigma) and
centrifuged at 800g for 20 min. The PBMC layer was transferred
to a fresh tube, washed 3 times with HBSS, frozen in RPMI 1640
(Invitrogen) with 20% foetal bovine serum (FBS; Invitrogen) and
10% dimethylsulfoxide (Sigma) and stored at80 C for 24 h before
transfer to liquid nitrogen. On thawing, cells were rested for two
hours at 37 C in RPMI 1640 with 10% FBS and 10 units/ml of ben-
zonase (Novagen), then washed and re-suspended in RPMI 1640
with 25 mM HEPES (Sigma) supplemented with 2 mM
L-glutamine and 10% filtered, heat-inactivated, pooled human AB
serum (Sigma). PBMC (1  106) were added to 2 ml screw-cap
microtubes (Sarstedt, Germany) with a pre-determined, optimal
quantity of BCG Danish that equated to 862 cfu and made up to a
final volume of 600 ll. Tubes were incubated at 37 C with 360
rotation for 96 h. Following incubations, cells and remaining BCG
were pelleted and cells lysed by incubation in sterile water with
vortexing. BCG from a single tube were then transferred into a cor-
responding MGIT tube and time to positivity determined using a
MGIT 960 (Becton Dickinson). As all assays were carried out simul-
taneously in a single batch, direct-to-MGIT controls were not used,
as the calculation of relative growth was not required.
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ICS flow cytometric data was analysed using FlowJo software
version 9 (TreeStar Inc.) and Spice version 5 [26]. Samples were
gated sequentially on singlet, live, CD14-CD19-, lymphoid, CD3
+ CD4+ cells and negative control stimulation tubes were used to
set cytokine gates (Supplementary Fig. 1). Median cytokine
responses in negative control tubes, as a percentage of the gated
CD4+ T-cell population, were as follows: IFNc – 0.003%; TNFa –
0.002%; IL-2 – 0.002%; IL-17 – 0.002%; IL-10 – 0.003%. Median cyto-
kine responses in positive control tubes (SEB-stimulated) were as
follows: IFNc – 0.16%; TNFa – 2.05%; IL-2 – 1.77%; IL-17 – 0.11%;
IL-10 – 0.06% (Supplementary Fig. 2). Cytokine responses reported
for all stimuli are after subtraction of background values measured
in un-stimulated tubes. The median number of CD4+ T-cell events
acquired for all tubes was 298,895 (IQR: 239875–312526).
All mycobacteria growth inhibition assays were carried out in
duplicate. For each tube, time to positivity in hours was converted
to log CFU of bacteria using a previously determined growth curve
for the stock of BCG used.
All statistical comparisons between the magnitudes of ICS and
growth inhibition responses between vaccinated and unvaccinated
groups were made using the Mann-Whitney U test. Associations
between growth inhibition and ICS responses were measured using
Spearman’s rank correlation coefficient.3. Results
3.1. BCG-vaccination of infants at 6 weeks of age induces
antigen-specific, polyfunctional Th-1 cells that persist up to at least
1 year post-vaccination
In order to assess the ability of infant BCG vaccination to acti-
vate cytokine-secreting helper T-cells we used a diluted whole
blood ICS assay and PPD stimulation to measure the frequency of
mycobacteria antigen-specific CD4+ T-cell responders at an early
and a later time point following vaccination. CD4+ T-cells express-
ing IFNc, TNFa and IL-2 were detectable at 4 months and 1 year
after vaccination but not in age-matched samples from unvacci-
nated infants (Fig. 1A–C). The application of Boolean gating to
determine the pattern of cytokine co-expression revealed that at
both 4 months and 1 year, IFNc+TNFa+IL-2+polyfunctional T-cells
formed the dominant responder population in BCG-vaccinated
infants. The overall responder profile, which also included TNFa
+IL-2+ double positive and TNFa+ single positive populations,
was almost identical at both time points after vaccination
(Fig. 1D). These data support the conclusion that BCG vaccination
of UK infants activates an antigen-specific, polyfunctional Th-1
response that is still detectable one year after vaccination.3.2. Antigen-specific Th-17 cells are increased in vaccinated infants at
4 months post-vaccination compared to unvaccinated controls
In addition to IFNc, TNFa and IL-2, we also examined
CD4+ T-cells for antigen-specific, IL-17 and IL-10 responses.
Although we could not detect any IL-10 response with this protocol
at either time point (data not shown), we did observe a signifi-
cantly greater frequency of IL-17+ CD4+ T-cells in vaccinated com-
pared to unvaccinated infants at 4 months (median responses of
0.011% IL-17+ and 0.002% IL-17+ CD4 T-cell respectively;
p = 0.0045) but not at 1 year (median responses of 0.007% IL-17
+ and 0.006% IL-17+ CD4 T-cell respectively; p = 0.894; Fig. 2A–C).
In order to determine whether IL-17+ CD4+ T-cells were secreting
other cytokines, we restricted analysis to all possible IL-17+ signa-
tures (Fig. 2D), which revealed that the dominant secretion profilewas IL-17+ single positive events. Although the response profile
was similar at both time points, there was a significant reduction
in the frequency of two less prominent populations at 1 year,
namely IL-17+TNFa+IL-2+ triple positive and IL-17+IL-2+ double
positive cells (p = 0.03 and p = 0.009 respectively; Fig. 2D). These
data support the conclusion that BCG vaccination of UK infants
activates an antigen-specific Th-17 response that, although promi-
nent at 4 months post-BCG, at 1-year post-BCG has reduced to a
magnitude that is indistinguishable from that seen in unvaccinated
infants.3.3. PBMC compartment of vaccinated infants displays an increased
capacity to inhibit the in vitro growth of BCG mycobacteria at 4
months post-vaccination
In parallel to diluted whole blood ICS assays, where sample vol-
ume permitted, PBMC were also prepared from infant blood sam-
ples and cryopreserved. These PBMC were later thawed and
tested for the capacity to inhibit mycobacterial growth in vitrowith
an assay used as a surrogate marker for protective immune
responses against Mycobacterium tuberculosis in vivo. Growth of
BCG mycobacteria was significantly inhibited by PBMC from
BCG-vaccinated infants at 4 months. The median log CFUmeasured
after 4-day culture was 3.2 as compared to 5.1 in unvaccinated
infants (p < 0.001; Fig. 3A). The difference in median log CFU at
12 months post-vaccination between vaccinated and age-
matched unvaccinated infants however was not significant (4.2
and 5.1 respectively; p = 0.294; Fig. 3B). As samples from vacci-
nated and unvaccinated infants at both time points exhibited a
range of log CFU values that represented the varying degrees of
mycobacterial inhibition, we compared these data with matching
frequencies of polyfunctional (IFNc+TNFa+IL-2+) and Th-17 (IL-
17+) CD4 T-cells for those samples where both MGIA and ICS data
were available. In order to avoid including dependent variables in
the correlation analysis, where data was available for one infant at
both time points, only the 4-month data was included. There was a
significant degree of inverse correlation between polyfunctional
CD4+ T-cell frequency and log CFU (Spearman r value = 0.709;
p = 0.013; Fig. 3C) but not between Th-17 CD4 T-cell frequency
and log CFU (Spearman r value = 0.399; p = 0.198; Fig. 3D) as
measured after growth inhibition assays.
In summary, BCG vaccination of UK infants induces polyfunc-
tional and Th-17 CD4 T-cells and bestows upon the PBMC compart-
ment the capacity to inhibit mycobacterial growth. Further to
these observations, there is an association between the magnitude
of the polyfunctional T-cell response and the level of mycobacterial
inhibition detected in vitro.4. Discussion
We have measured a population of PPD-specific, CD4+ T-cells
that demonstrates polyfunctional (IFNc+TNFa+IL-2+) capabilities
in infants who have received BCG vaccination at 6 weeks of age.
This population was detectable at 4 months and 1 year post-
vaccination, comprised the most abundant population as com-
pared to other possible secretion profiles at both time points and
was absent in unvaccinated infants. This result complements pre-
vious immune analyses we have carried out on similar infant
cohorts where secreted cytokine responses, including IFNc, TNFa
and IL-2, were observed in vaccinated but not unvaccinated infants
following PPD stimulation of diluted whole blood [27,28], and
partly answers the question as to which cells were secreting
cytokines in those studies. A number of papers have consistently
described a more heterogeneous T-helper response in terms of
the cytokine secretion profiles detected following BCG in infants
Fig. 1. Persistent, polyfunctional T helper-1 cells are the dominant, PPD-specific CD4+ T-cell population in BCG-vaccinated infants. Venous blood samples obtained 4 months
and 1-year post-BCG from vaccinated infants or from age-matched, unvaccinated infants were stimulated with PPD overnight and CD4+ T-cells assessed for cytokine
secretion by intracellular staining. An example of IFNc, TNFa and IL-2 co-staining is shown for 4 month (A) and 1 year (B) samples from a BCG vaccinated (+) and an
unvaccinated () infant and cumulative composite, single cytokine expression data (C) for vaccinated and unvaccinated infants at 4 months (dark grey circles) and 1 year
(light grey circles). (D) The polyfunctionality of CD4+ T-cell cytokine responses in BCG-vaccinated infants at 4 months (dark grey bars) and 1 year (light grey bars). All
composite data plots display boxes showing medians and interquartile ranges. Whiskers, where included, show the data range. The Mann-Whitney U test was used to
determine significance. Sample numbers are n = 24 (BCG-vaccinated infants at 4 months post-BCG); n = 18 (BCG-vaccinated infants at 1 year post-BCG); n = 12 (BCG-
unvaccinated infants at 4 month time point) and n = 15 (BCG-unvaccinated infants at 1 year time point).
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Fig. 2. PPD-specific T helper-17 response in BCG-vaccinated infants. An example of IL-17, IFNc, TNFa and IL-2 co-staining is shown for 4 month (A) and 1 year (B) samples
from a vaccinated (+) and an unvaccinated () infant. (C) Cumulative, composite IL-17 expression data for vaccinated and unvaccinated infants at 4 months (dark grey circles)
and 1 year (light grey circles). (D) The polyfunctionality of all IL-17-expressing CD4+ T-cell phenotypes in BCG vaccinated infants at 4 months (dark grey bars) and 1 year
(light grey bars). Sample numbers are n = 24 (BCG-vaccinated infants at 4 months post-BCG); n = 18 (BCG-vaccinated infants at 1 year post-BCG); n = 12 (BCG-unvaccinated
infants at 4 month time point) and n = 15 (BCG-unvaccinated infants at 1 year time point). Statistics for comparisons between vaccinated and unvaccinated infants are Mann-
Whitney U tests. ⁄ indicates p < 0.05.
5302 S.G. Smith et al. / Vaccine 34 (2016) 5298–5305[15,29–31]. Although IFNc+TNFa+IL-2+ triple positive cells are
usually detectable in those studies, it is often single cytokine pro-
ducers, most notably IFNc+ Th-1 cells, which are most frequent. In
contrast, we did not detect any single IFNc producers and in fact,
the only population that displayed any IFNc positivity was
expressing all three cytokines. The studies referred to above were
carried out in Africa, therefore it is possible that these differences
in response could be due to the fact that our study was carried
out in a northern European setting and so infant participants com-
prised a different ethnic population who were exposed to a con-
trasting set of environmental factors. Another possible
explanation for the difference between these results and those
from the African settings could be differences in stimulation proto-
cols, most notably the use of live BCG mycobacteria as a stimulant
in the African studies and our use of PPD. In addition to this study,
others who have used PPD as a stimulant to investigate T-cell
responses following BCG vaccination have also reported prominent
polyfunctional responses in mice and humans [32,33].
Clearly, the implication of observing a persistent, polyfunctional
population of Th-1 cells that is very specific to having received the
BCG vaccine, is that these cells are in some way involved in the
protection that BCG affords these infants against childhood TB[2]. One of the first flow cytometric descriptions of polyfunctional,
cytokine-producing T-cells was in the context of the protection
they conferred to mice following efficacious vaccination against
Leishmania major [34]. The field of TB has produced mixed data
regarding the role of polyfunctional cells in immune protection.
Retrospective analysis of samples taken 10 weeks after BCG vacci-
nation at birth showed no difference in polyfunctional Th-1 cell
frequency when infants who eventually contracted TB disease
were compared to those who were exposed but remained
disease-free during a 2 year follow-up period [15]. Another recent
example of polyfunctional Th-1 cells failing to bestow protection
against TB was when no significant protective effect was demon-
strated following administration of novel TB vaccine MVA85A to
infants despite this vaccine’s ability to boost antigen-specific,
IFNc+TNFa+IL-2+CD4 T-cells [6]. Evidently, polyfunctional Th-1
cells do not correlate with risk of TB disease or protection, respec-
tively, in these studies carried out in African settings, however,
there are other circumstances where polyfunctional T-cell
responses are associated with groups who have proved resistant
to the development of TB disease; namely HIV-positive patients
after anti-retroviral therapy with higher CD4 counts or those with
lower viral loads [35,36]. The relatively low TB incidence in the UK
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Fig. 3. Increased capacity to inhibit the in vitro growth of mycobacteria in PBMC from BCG-vaccinated infants that correlates with polyfunctional T-cell response.
Cryopreserved PBMC prepared from venous blood samples obtained 4 months and 1 year post-BCG from vaccinated infants or from age-matched, unvaccinated infants were
recovered and incubated with BCG for 4 days after which remaining mycobacteria were quantified by BACTEC MGIT tubes. Inhibition of BCG growth is indicated by the log
CFU of remaining mycobacteria after incubation with PBMC obtained at the 4 month (A) or 12 month (B) time point from BCG-vaccinated (+) or BCG-unvaccinated () infants.
Sample numbers are n = 8 (BCG-vaccinated infants at 4 months post-BCG); n = 8 (BCG-vaccinated infants at 1 year post-BCG); n = 7 (BCG-unvaccinated infants at 4 month
time point) and n = 7 (BCG-unvaccinated infants at 1 year time point). For all infant samples where growth inhibition and ICS data was available (n = 12), scatter plots of log
CFU versus frequency of polyfunctional CD4+ T-cells (C) or versus IL-17+CD4+T-cells (D) were drawn. Solid symbols indicate 4-month samples; open symbols indicate 12-
month samples; circles indicate samples from vaccinated infants; triangles indicate samples from unvaccinated infants. The Mann-Whitney U test was used to compare
growth inhibition between vaccinated and un-vaccinated groups. Spearman’s rank correlation coefficient was calculated between growth inhibition and ICS frequencies and
significant correlations (p < 0.05) are indicated (⁄).
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determine whether the Th-1 population we describe here corre-
lates inversely or directly with risk or protection respectively,
although it seems that the field would benefit greatly from an
assessment of the protective capacity of polyfunctional T-cells in
a low NTM, high latitude setting.
In mice, IL-17 responses in the lung were shown to precede an
influx of protective Th-1 cells following vaccination and subse-
quent infection with M. tb [37] and furthermore, the IL-23/IL-17
pathway was necessary following BCG vaccination for the effective
generation of a Th-1 response specifically to overcome an other-
wise inhibitory IL-10 response [38]. In addition to polyfunctional
Th-1 cells, we also report here a population of PPD-specific, IL-17
+ CD4+ CD3+ cells that are present at a significantly greater fre-
quency in BCG-vaccinated infants at 4 months post-BCG, as com-
pared to age-matched, unvaccinated infants. Again, this is
consistent with our previous reports of PPD-specific, IL-17
responses detectable in BCG-vaccinated infants [27,28]. The cur-
rent data provide evidence that the source of at least some of this
IL-17 is antigen-specific Th-17 cells. Unlike Th-1 cellular profiles,
Th-17 cells have been less frequently reported in infant BCG stud-
ies, partly due to the more recent emergence of IL-17 as a cytokineof interest. Where a Th-17 response was sought, in one report it
was not detectable above background levels in control stimula-
tions [39], however in others it was detectable but did not correlate
with risk of TB disease in South African infants [15], nor did it differ
in Ugandan infants who received BCG at birth as compared to those
who received it at 6 weeks of age [31]. We have previously
described the complete absence of a PPD-specific, secreted IFNc
response in unvaccinated UK infants up to 15 months of age [40]
and describe here a concomitant absence of IFNc+Th-1 cells in a
similar cohort. This very low background immune responsiveness
to PPD extends to IL-17 and has allowed us to distinguish an other-
wise low frequency Th-17 response at 4 months in vaccinated
infants. However, this differential response at 4 months post-BCG
did not extend to samples taken at 1-year post-BCG. It is interest-
ing to note that whilst the frequency of the Th-17 response in BCG-
vaccinated infants is lower at 12 months than at 4 months, the
inverse is true of unvaccinated infants. It has been shown that
there is a strong bias towards the development of Th-17 in neo-
nates [41]. In our study, it may be that this propensity is being
illustrated in two ways. Firstly, in the large increase in PPD-
specific Th-17 responses due to BCG vaccination that gradually
wanes by 12 months. Secondly, in the less pronounced increase
5304 S.G. Smith et al. / Vaccine 34 (2016) 5298–5305in Th-17 responses in BCG unvaccinated infants. That the latter
responses were stimulated by PPD suggests that either these
infants have been exposed to environmental mycobacteria or that
there is some cross-reactivity in these Th-17 responses.
We did not detect any IL-10 responses in this study. Although
we previously detected PPD-induced IL-10 in BCG vaccinated
infants it was in diluted whole blood culture supernatants after
7 days using multiplex bead array. [27,28]. In this study we used
a much shorter stimulation period (18 h) and ICS as a detection
method and these may be a less sensitive than is required for IL-
10. Another possible explanation is that we restricted our analysis
to CD4+ T-cells in this study and may be missing IL-10 responses
from cells such as monocytes.
In the absence of a TB disease or infection outcome in our
cohort we employed instead an in vitro mycobacteria growth inhi-
bition assay (MGIA) as a surrogate marker of immune resistance.
There is much interest in developing functional assays such as
the MGIA as a surrogate marker of protection in order to facilitate
the testing of novel TB vaccines. The aim is that the MGIA will
eventually circumvent the need for long, expensive follow up peri-
ods with TB disease or infection as an endpoint. An additional
advantage is that the unbiased nature of the MGIA means that
prior knowledge as to which component of the immune system
is responsible for any protective effect is not necessary. In this
study, we found that the PBMC compartment of vaccinated infants
contained the ability to inhibit the growth of BCG mycobacteria
in vitro to a greater extent than that of unvaccinated infants in
samples taken at 4 months. However by 12-month post-BCG there
was no difference between the vaccinated and unvaccinated
groups. A previous study has shown that PBMC from adults with
a history of BCG vaccination inhibit the growth of BCG mycobacte-
ria in vitro to a greater extent than PBMC from adults without a his-
tory of BCG vaccination and that the capacity to inhibit
mycobacterial growth can be induced in the BCG ‘naïve’ adults
with subsequent, primary vaccination [42]. In another study using
a different version of the growth inhibition assay involving lumi-
nescent BCG and whole blood samples, neonatal BCG vaccination
induced a significant degree of mycobacterial growth inhibition
that persisted for up to 6 months when compared to growth inhi-
bition in pre-vaccination samples [43]. Based on the data available,
it is difficult to speculate as to why adults who have had BCG many
years previously may display significantly more growth inhibition
than adults with no history of BCG where as in this study, the dif-
ference between vaccinated and unvaccinated infants lost statisti-
cal significance by 12 months post vaccination. The interquartile
range of the 12-month post-BCG growth inhibition data was much
greater in the vaccinated group. This may be due to the relatively
small sample size and a bigger study with more infants might
allow smaller differences between groups to be detectable that
are not here. It should be noted however that in the Fletcher
et al study [42], adults receiving primary BCG vaccination that dis-
played significant PBMC-mediated growth inhibition at 4 weeks
post-vaccination had returned to baseline levels by 6 months
post-vaccination which is more consistent with the findings we
present here.
The data presented here support the hypothesis that PPD-
specific polyfunctional CD4 T-cells secreting IFNc, TNFa and IL-2
play a role in mycobacterial growth inhibition in vitro. It is interest-
ing that three previous studies [21,42,43] did not show any corre-
lation between PPD-specific IFNc responses measured by ELISA or
ELISpot and growth inhibition. To our knowledge, this is the first
time growth inhibition and polyfunctional CD4 T-cells have been
compared in infants and that a correlation is detected might indi-
cate that measuring these cells is revealing a mechanism that look-
ing at IFNc alone might be missing.Our data involves a correlation between ICS responses mea-
sured in diluted whole blood and MGIA responses measured in
PBMC, two different cellular compartments. We cannot rule out
possible implications (and limitations) of this, for example, the
presence of polymorphonuclear cells in ICS assays and their
absence in MGIA or the use of non-autologous pooled human
serum in MGIA. It would be worth, in future, repeating this exper-
iment using a whole blood version of the growth inhibition assay
to complement the whole blood ICS in order to investigate the pos-
sible impact of this.
In conclusion, the present study expands our previous descrip-
tion of cytokine and chemokine immune responses in BCG vacci-
nated UK infants to reveal a prominent, long-lived and mainly
polyfunctional Th-1 response together with the induction of
antigen-specific Th-17 cells and that the magnitude of polyfunc-
tional Th-1 cells correlates with in vitromycobacterial growth inhi-
bition and may play a role in this effect.Conflicts of interest
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